Biogen (NASDAQ: BIIB) recently suffered a brutal stock market beating after its big Alzheimer's candidate failed to make a difference for patients with early signs of the disease.
Biogen's market value was reduced by nearly a third in a few short days, and that puts it in range for a big pharma buyout. If Biogen follows the standard industry handbook, management will acquire a medium-sized biotech soon.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,